Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Receivables (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Receivables for 6 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 30.07% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 30.07% year-over-year, with the annual reading at $1.1 million for FY2025, 30.07% down from the prior year.
  • Receivables hit $1.1 million in Q4 2025 for Insight Molecular Diagnostics, up from $258000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $3.5 million in Q1 2025 to a low of $85000.0 in Q2 2024.
  • Historically, Receivables has averaged $1.1 million across 5 years, with a median of $1.0 million in 2021.
  • Biggest five-year swings in Receivables: skyrocketed 5307.69% in 2021 and later tumbled 88.5% in 2024.
  • Year by year, Receivables stood at $1.4 million in 2021, then dropped by 2.57% to $1.4 million in 2022, then plummeted by 65.07% to $489000.0 in 2023, then skyrocketed by 229.86% to $1.6 million in 2024, then plummeted by 30.07% to $1.1 million in 2025.
  • Business Quant data shows Receivables for IMDX at $1.1 million in Q4 2025, $258000.0 in Q3 2025, and $512000.0 in Q2 2025.